{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:23:06Z","timestamp":1790310186292,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,9,4]],"date-time":"2017-09-04T00:00:00Z","timestamp":1504483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,9,4]],"date-time":"2017-09-04T00:00:00Z","timestamp":1504483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    A short half-life in the circulation limits the application of therapeutics such as single-domain antibodies (VHHs). We utilize red blood cells to prolong the circulatory half-life of VHHs. Here we present VHHs against botulinum neurotoxin A (BoNT\/A) on the surface of red blood cells by expressing chimeric proteins of VHHs with Glycophorin A or Kell. Mice whose red blood cells carry the chimeric proteins exhibit resistance to 10,000 times the lethal dose (LD\n                    <jats:sub>50<\/jats:sub>\n                    ) of BoNT\/A, and transfusion of these red blood cells into naive mice affords protection for up to 28 days. We further utilize an improved CD34+ culture system to engineer human red blood cells that express these chimeric proteins. Mice transfused with these red blood cells are resistant to highly lethal doses of BoNT\/A. We demonstrate that engineered red blood cells expressing VHHs can provide prolonged prophylactic protection against bacterial toxins without inducing inhibitory immune responses and illustrates the potentially broad translatability of our strategy for therapeutic applications.\n                  <\/jats:p>","DOI":"10.1038\/s41467-017-00448-0","type":"journal-article","created":{"date-parts":[[2017,8,29]],"date-time":"2017-08-29T15:26:45Z","timestamp":1504020405000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Genetically engineered red cells expressing single domain camelid antibodies confer long-term protection against botulinum neurotoxin"],"prefix":"10.1038","volume":"8","author":[{"given":"Nai-Jia","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Novalia","family":"Pishesha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sicai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhogerry","family":"Deshycka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentino","family":"Sudaryo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles B.","family":"Shoemaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey F.","family":"Lodish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,4]]},"reference":[{"key":"448_CR1","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/363446a0","volume":"363","author":"C Hamers-Casterman","year":"1993","unstructured":"Hamers-Casterman, C. et al. Naturally occurring antibodies devoid of light chains. Nature 363, 446\u2013448 (1993).","journal-title":"Nature"},{"key":"448_CR2","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","volume":"82","author":"S Muyldermans","year":"2013","unstructured":"Muyldermans, S. Nanobodies: natural single-domain antibodies. Annu. Rev. Biochem. 82, 775\u2013797 (2013).","journal-title":"Annu. Rev. Biochem."},{"key":"448_CR3","doi-asserted-by":"publisher","first-page":"e29941","DOI":"10.1371\/journal.pone.0029941","volume":"7","author":"J Mukherjee","year":"2012","unstructured":"Mukherjee, J. et al. A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model. PLoS ONE 7, e29941 (2012).","journal-title":"PLoS ONE"},{"key":"448_CR4","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1128\/IAI.01033-13","volume":"81","author":"JM Tremblay","year":"2013","unstructured":"Tremblay, J. M. et al. A single VHH-based toxin-neutralizing agent and an effector antibody protect mice against challenge with Shiga toxins 1 and 2. Infect. Immun. 81, 4592\u20134603 (2013).","journal-title":"Infect. Immun."},{"key":"448_CR5","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1093\/infdis\/jiu196","volume":"210","author":"Z Yang","year":"2014","unstructured":"Yang, Z. et al. A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice. J. Infect. Dis. 210, 964\u2013972 (2014).","journal-title":"J. Infect. Dis."},{"key":"448_CR6","doi-asserted-by":"publisher","first-page":"6584","DOI":"10.1074\/jbc.M114.627943","volume":"290","author":"M Moayeri","year":"2015","unstructured":"Moayeri, M. et al. A heterodimer of a VHH (variable domains of camelid heavy chain-only) antibody that inhibits anthrax toxin cell binding linked to a VHH antibody that blocks oligomer formation is highly protective in an anthrax spore challenge model. J. Biol. Chem. 290, 6584\u20136595 (2015).","journal-title":"J. Biol. Chem."},{"key":"448_CR7","doi-asserted-by":"publisher","first-page":"27880","DOI":"10.1074\/jbc.M115.658070","volume":"290","author":"C Herrera","year":"2015","unstructured":"Herrera, C., Tremblay, J. M., Shoemaker, C. B. & Mantis, N. J. Mechanisms of ricin toxin neutralization revealed through engineered homodimeric and heterodimeric camelid antibodies. J. Biol. Chem. 290, 27880\u201327889 (2015).","journal-title":"J. Biol. Chem."},{"key":"448_CR8","doi-asserted-by":"publisher","first-page":"386","DOI":"10.7150\/thno.8006","volume":"4","author":"R Chakravarty","year":"2014","unstructured":"Chakravarty, R., Goel, S. & Cai, W. Nanobody: the \u201cmagic bullet\u201d for molecular imaging? Theranostics 4, 386\u2013398 (2014).","journal-title":"Theranostics"},{"key":"448_CR9","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1046\/j.1471-4159.1999.0720327.x","volume":"72","author":"VV Vaidyanathan","year":"1999","unstructured":"Vaidyanathan, V. V. et al. Proteolysis of SNAP-25 isoforms by botulinum neurotoxin types A, C, and E: domains and amino acid residues controlling the formation of enzyme-substrate complexes and cleavage. J. Neurochem. 72, 327\u2013337 (1999).","journal-title":"J. Neurochem."},{"key":"448_CR10","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3390\/toxins3050469","volume":"3","author":"J Thanongsaksrikul","year":"2011","unstructured":"Thanongsaksrikul, J. & Chaicumpa, W. Botulinum neurotoxins and botulism: a novel therapeutic approach. Toxins 3, 469\u2013488 (2011).","journal-title":"Toxins"},{"key":"448_CR11","doi-asserted-by":"publisher","first-page":"e106422","DOI":"10.1371\/journal.pone.0106422","volume":"9","author":"J Mukherjee","year":"2014","unstructured":"Mukherjee, J. et al. Prolonged prophylactic protection from botulism with a single adenovirus treatment promoting serum expression of a VHH-based antitoxin protein. PLoS ONE 9, e106422 (2014).","journal-title":"PLoS ONE"},{"key":"448_CR12","doi-asserted-by":"publisher","first-page":"e17491","DOI":"10.1371\/journal.pone.0017491","volume":"6","author":"SP Adekar","year":"2011","unstructured":"Adekar, S. P. et al. Enhanced neutralization potency of botulinum neurotoxin antibodies using a red blood cell-targeting fusion protein. PLoS ONE 6, e17491 (2011).","journal-title":"PLoS ONE"},{"key":"448_CR13","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/sj.gt.3302180","volume":"11","author":"HM Byun","year":"2004","unstructured":"Byun, H. M. et al. Erythrocyte ghost-mediated gene delivery for prolonged and blood-targeted expression. Gene Ther 11, 492\u2013496 (2004).","journal-title":"Gene Ther"},{"key":"448_CR14","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1517\/17425241003610633","volume":"7","author":"VR Muzykantov","year":"2010","unstructured":"Muzykantov, V. R. Drug delivery by red blood cells: vascular carriers designed by mother nature. Expert Opin. Drug Deliv. 7, 403\u2013427 (2010).","journal-title":"Expert Opin. Drug Deliv."},{"key":"448_CR15","doi-asserted-by":"publisher","first-page":"E60","DOI":"10.1073\/pnas.1216353110","volume":"110","author":"S Kontos","year":"2013","unstructured":"Kontos, S., Kourtis, I. C., Dane, K. Y. & Hubbell, J. A. Engineering antigens for in situ erythrocyte binding induces T-cell deletion. Proc. Natl Acad. Sci. USA 110, E60\u201368 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"448_CR16","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.tcb.2011.04.003","volume":"21","author":"P Ji","year":"2011","unstructured":"Ji, P., Murata-Hori, M. & Lodish, H. F. Formation of mammalian erythrocytes: chromatin condensation and enucleation. Trends Cell Biol. 21, 409\u2013415 (2011).","journal-title":"Trends Cell Biol."},{"key":"448_CR17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.addr.2016.02.007","volume":"106","author":"CH Villa","year":"2016","unstructured":"Villa C. H., Anselmo A. C., Mitragotri S. & Muzykantov V. Red blood cells: supercarriers for drugs, biologicals, and nanoparticles and inspiration for advanced delivery systems. Adv. Drug Deliv. Rev. 106, 88\u2013103 (2016).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"448_CR18","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1046\/j.1537-2995.1999.39299154730.x","volume":"39","author":"H Cowley","year":"1999","unstructured":"Cowley, H., Wojda, U., Cipolone, K. M., Procter, J. L., Stroncek, D. F. & Miller, J. L. Biotinylation modifies red cell antigens. Transfusion 39, 163\u2013168 (1999).","journal-title":"Transfusion"},{"key":"448_CR19","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1470-8744.1996.tb00386.x","volume":"24","author":"VR Muzykantov","year":"1996","unstructured":"Muzykantov, V. R. & Murciano, J. C. Attachment of antibody to biotinylated red blood cells: immuno-red blood cells display high affinity to immobilized antigen and normal biodistribution in rats. Biotechnol. Appl. Biochem. 24, 41\u201345 (1996).","journal-title":"Biotechnol. Appl. Biochem."},{"key":"448_CR20","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/nbt846","volume":"21","author":"JC Murciano","year":"2003","unstructured":"Murciano, J. C., Medinilla, S., Eslin, D., Atochina, E., Cines, D. B. & Muzykantov, V. R. Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes. Nat. Biotechnol. 21, 891\u2013896 (2003).","journal-title":"Nat. Biotechnol."},{"key":"448_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00253-007-1142-2","volume":"77","author":"MM Harmsen","year":"2007","unstructured":"Harmsen, M. M. & De Haard, H. J. Properties, production, and applications of camelid single-domain antibody fragments. Appl. Microbiol. Biotechnol. 77, 13\u201322 (2007).","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"448_CR22","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1128\/AAC.02830-14","volume":"58","author":"SU Nayak","year":"2014","unstructured":"Nayak, S. U. et al. Safety and pharmacokinetics of XOMA 3AB, a novel mixture of three monoclonal antibodies against botulinum toxin A. Antimicrob. Agents Chemother. 58, 5047\u20135053 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"448_CR23","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/ajh.2830420110","volume":"42","author":"S Piomelli","year":"1993","unstructured":"Piomelli, S. & Seaman, C. Mechanism of red blood cell aging: relationship of cell density and cell age. Am. J. Hematol. 42, 46\u201352 (1993).","journal-title":"Am. J. Hematol."},{"key":"448_CR24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/ajh.21298","volume":"84","author":"RS Franco","year":"2009","unstructured":"Franco, R. S. The measurement and importance of red cell survival. Am. J. Hematol. 84, 109\u2013114 (2009).","journal-title":"Am. J. Hematol."},{"key":"448_CR25","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3389\/fphys.2013.00376","volume":"4","author":"GJ Bosman","year":"2013","unstructured":"Bosman, G. J. Survival of red blood cells after transfusion: processes and consequences. Front. Physiol. 4, 376 (2013).","journal-title":"Front. Physiol."},{"key":"448_CR26","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/nature14326","volume":"522","author":"HY Lee","year":"2015","unstructured":"Lee, H. Y. et al. PPAR-alpha and glucocorticoid receptor synergize to promote erythroid progenitor self-renewal. Nature 522, 474\u2013477 (2015).","journal-title":"Nature"},{"key":"448_CR27","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/978-1-59745-060-7_8","volume":"482","author":"L Douay","year":"2009","unstructured":"Douay, L. & Giarratana, M. C. Ex vivo generation of human red blood cells: a new advance in stem cell engineering. Methods Mol. Biol. 482, 127\u2013140 (2009).","journal-title":"Methods Mol. Biol."},{"key":"448_CR28","doi-asserted-by":"publisher","first-page":"e76062","DOI":"10.1371\/journal.pone.0076062","volume":"8","author":"B Malleret","year":"2013","unstructured":"Malleret, B. et al. Significant biochemical, biophysical and metabolic diversity in circulating human cord blood reticulocytes. PLoS ONE 8, e76062 (2013).","journal-title":"PLoS ONE"},{"key":"448_CR29","doi-asserted-by":"publisher","first-page":"6296","DOI":"10.1182\/blood-2011-09-376475","volume":"119","author":"RE Griffiths","year":"2012","unstructured":"Griffiths, R. E. et al. Maturing reticulocytes internalize plasma membrane in glycophorin A-containing vesicles that fuse with autophagosomes before exocytosis. Blood 119, 6296\u20136306 (2012).","journal-title":"Blood"},{"key":"448_CR30","doi-asserted-by":"publisher","first-page":"476","DOI":"10.3324\/haematol.2016.154443","volume":"102","author":"S Kupzig","year":"2017","unstructured":"Kupzig, S., Parsons, S. F., Curnow, E., Anstee, D. J. & Blair, A. Superior survival of ex vivo cultured human reticulocytes following transfusion into mice. Haematologica 102, 476\u2013483 (2017).","journal-title":"Haematologica"},{"key":"448_CR31","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1182\/blood-2013-01-476390","volume":"121","author":"J Hu","year":"2013","unstructured":"Hu, J. et al. Isolation and functional characterization of human erythroblasts at distinct stages: implications for understanding of normal and disordered erythropoiesis in vivo. Blood 121, 3246\u20133253 (2013).","journal-title":"Blood"},{"key":"448_CR32","doi-asserted-by":"publisher","first-page":"10131","DOI":"10.1073\/pnas.1409861111","volume":"111","author":"JH Shi","year":"2014","unstructured":"Shi, J. H. et al. Engineered red blood cells as carriers for systemic delivery of a wide array of functional probes. Proc. Natl Acad. Sci. USA 111, 10131\u201310136 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"448_CR33","doi-asserted-by":"publisher","first-page":"9876","DOI":"10.1074\/jbc.275.13.9876","volume":"275","author":"H Ton-That","year":"2000","unstructured":"Ton-That, H., Mazmanian, S. K., Faull, K. F. & Schneewind, O. Anchoring of surface proteins to the cell wall of Staphylococcus aureus. Sortase catalyzed in vitro transpeptidation reaction using LPXTG peptide and NH(2)-Gly(3) substrates. J. Biol. Chem. 275, 9876\u20139881 (2000).","journal-title":"J. Biol. Chem."},{"key":"448_CR34","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1073\/pnas.1701746114","volume":"114","author":"N Pishesha","year":"2017","unstructured":"Pishesha, N. et al. Engineered erythrocytes covalently linked to antigenic peptides can protect against autoimmune disease. Proc. Natl Acad. Sci. USA 114, 3157\u20133162 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"448_CR35","doi-asserted-by":"publisher","first-page":"10980","DOI":"10.1073\/pnas.1106634108","volume":"108","author":"CMJ Hu","year":"2011","unstructured":"Hu, C. M. J., Zhang, L., Aryal, S., Cheung, C., Fang, R. H. & Zhang, L. F. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc. Natl Acad. Sci. USA 108, 10980\u201310985 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"448_CR36","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1128\/IAI.02360-14","volume":"83","author":"AS Sheoran","year":"2015","unstructured":"Sheoran, A. S. et al. Adenovirus vector expressing Stx1\/Stx2-neutralizing agent protects piglets infected with Escherichia coli O157:H7 against fatal systemic intoxication. Infect. Immun. 83, 286\u2013291 (2015).","journal-title":"Infect. Immun."},{"key":"448_CR37","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1128\/CVI.00730-15","volume":"23","author":"DJ Schmidt","year":"2016","unstructured":"Schmidt, D. J. et al. A tetraspecific VHH-based neutralizing antibody modifies disease outcome in three animal models of clostridium difficile infection. Clin. Vaccine Immunol. 23, 774\u2013784 (2016).","journal-title":"Clin. Vaccine Immunol."},{"key":"448_CR38","doi-asserted-by":"publisher","first-page":"314","DOI":"10.4161\/self.1.4.13904","volume":"1","author":"MP Baker","year":"2010","unstructured":"Baker, M. P., Reynolds, H. M., Lumicisi, B. & Bryson, C. J. Immunogenicity of protein therapeutics: The key causes, consequences and challenges. Self Nonself 1, 314\u2013322 (2010).","journal-title":"Self Nonself"},{"key":"448_CR39","doi-asserted-by":"publisher","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","volume":"2","author":"FA Harding","year":"2010","unstructured":"Harding, F. A., Stickler, M. M., Razo, J. & DuBridge, R. B. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs 2, 256\u2013265 (2010).","journal-title":"MAbs"},{"key":"448_CR40","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nbt1047","volume":"23","author":"MC Giarratana","year":"2005","unstructured":"Giarratana, M. C. et al. Ex vivo generation of fully mature human red blood cells from hematopoietic stem cells. Nat. Biotechnol. 23, 69\u201374 (2005).","journal-title":"Nat. Biotechnol."},{"key":"448_CR41","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/jgm.2691","volume":"15","author":"GJ McGarrity","year":"2013","unstructured":"McGarrity, G. J. et al. Patient monitoring and follow-up in lentiviral clinical trials. J. Gene Med. 15, 78\u201382 (2013).","journal-title":"J. Gene Med."},{"key":"448_CR42","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/nature15818","volume":"526","author":"L Naldini","year":"2015","unstructured":"Naldini, L. Gene therapy returns to centre stage. Nature 526, 351\u2013360 (2015).","journal-title":"Nature"},{"key":"448_CR43","doi-asserted-by":"publisher","first-page":"5071","DOI":"10.1182\/blood-2011-06-362038","volume":"118","author":"MC Giarratana","year":"2011","unstructured":"Giarratana, M. C. et al. Proof of principle for transfusion of in vitro-generated red blood cells. Blood 118, 5071\u20135079 (2011).","journal-title":"Blood"},{"key":"448_CR44","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood.V92.10.3829.422k14_3829_3840","volume":"92","author":"X Zhang","year":"1998","unstructured":"Zhang, X. & Ren, R. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood 92, 3829\u20133840 (1998).","journal-title":"Blood"},{"key":"448_CR45","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/nm.3557","volume":"20","author":"LS Ludwig","year":"2014","unstructured":"Ludwig, L. S. et al. Altered translation of GATA1 in Diamond-Blackfan anemia. Nat. Med. 20, 748\u2013753 (2014).","journal-title":"Nat. Med."},{"key":"448_CR46","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1038\/ncomms2462","volume":"4","author":"L Peng","year":"2013","unstructured":"Peng, L. et al. Cytotoxicity of botulinum neurotoxins reveals a direct role of syntaxin 1 and SNAP-25 in neuron survival. Nat. Commun. 4, 1472 (2013).","journal-title":"Nat. Commun."},{"key":"448_CR47","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1172\/JCI76979","volume":"124","author":"YY Yien","year":"2014","unstructured":"Yien, Y. Y. et al. TMEM14C is required for erythroid mitochondrial heme metabolism. J. Clin. Invest. 124, 4294\u20134304 (2014).","journal-title":"J. Clin. Invest."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-00448-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-00448-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-00448-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T11:03:18Z","timestamp":1719399798000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-00448-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,4]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["448"],"URL":"https:\/\/doi.org\/10.1038\/s41467-017-00448-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,4]]},"assertion":[{"value":"6 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.F.L. declares a competing financial interest as a shareholder in Rubius, Inc., a company that seeks to use modified red blood cells for therapeutic use. The remaining authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"423"}}